Kexing Biopharm Makes it into China’s Top 20 Biopharmaceutical Enterprises (Blood Products, Vaccines and Insulin) for Two Consecutive Years

SHENZHEN, China, July 7, 2023 /PRNewswire/ — Kexing Biopharmaceutical (688136.SH) has accomplished the impressive feat of being recognized on June 27 as one of “China’s Top 20 Biopharmaceutical Enterprises” (blood products, vaccines and insulin) for two consecutive years. This…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.